全文获取类型
收费全文 | 3806篇 |
免费 | 292篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 219篇 |
妇产科学 | 44篇 |
基础医学 | 509篇 |
口腔科学 | 136篇 |
临床医学 | 340篇 |
内科学 | 796篇 |
皮肤病学 | 143篇 |
神经病学 | 125篇 |
特种医学 | 210篇 |
外科学 | 478篇 |
综合类 | 253篇 |
一般理论 | 1篇 |
预防医学 | 161篇 |
眼科学 | 44篇 |
药学 | 233篇 |
1篇 | |
中国医学 | 61篇 |
肿瘤学 | 321篇 |
出版年
2023年 | 21篇 |
2022年 | 42篇 |
2021年 | 80篇 |
2020年 | 62篇 |
2019年 | 52篇 |
2018年 | 91篇 |
2017年 | 61篇 |
2016年 | 85篇 |
2015年 | 93篇 |
2014年 | 151篇 |
2013年 | 157篇 |
2012年 | 263篇 |
2011年 | 256篇 |
2010年 | 166篇 |
2009年 | 159篇 |
2008年 | 192篇 |
2007年 | 215篇 |
2006年 | 183篇 |
2005年 | 189篇 |
2004年 | 155篇 |
2003年 | 144篇 |
2002年 | 111篇 |
2001年 | 94篇 |
2000年 | 94篇 |
1999年 | 95篇 |
1998年 | 69篇 |
1997年 | 80篇 |
1996年 | 75篇 |
1995年 | 52篇 |
1994年 | 48篇 |
1993年 | 40篇 |
1992年 | 40篇 |
1991年 | 42篇 |
1990年 | 36篇 |
1989年 | 48篇 |
1988年 | 35篇 |
1987年 | 55篇 |
1986年 | 28篇 |
1985年 | 35篇 |
1984年 | 26篇 |
1983年 | 11篇 |
1982年 | 14篇 |
1981年 | 15篇 |
1980年 | 19篇 |
1979年 | 17篇 |
1977年 | 10篇 |
1976年 | 13篇 |
1975年 | 14篇 |
1974年 | 11篇 |
1971年 | 13篇 |
排序方式: 共有4137条查询结果,搜索用时 31 毫秒
141.
142.
143.
Balakrishnan V Unnikrishnan AG Thomas V Choudhuri G Veeraraju P Singh SP Garg P Pai CG Devi RN Bhasin D Jayanthi V Premalatha N Chacko A Kar P Rai RR Rajan R Subhalal N Mehta R Mishra SP Dwivedi M Vinayakumar KR Jain AK Biswas K Mathai S Varghese J Ramesh H Alexander T Philip J Raj VV Vinodkumar A Mukevar S Sawant P Nair P Kumar H Sudhindran S Dhar P Sudheer OV Sundaram KR Tantri BV Singh D Nath TR 《JOP : Journal of the pancreas》2008,9(5):593-600
144.
145.
146.
Bird HA Leeb BF Montecucco CM Misiuniene N Nesher G Pai S Pease C Rovensky J Rozman B 《Annals of the rheumatic diseases》2005,64(4):626-629
OBJECTIVE: To compare the performance of the several different diagnostic criteria sets currently in use for polymyalgia rheumatica (PMR). METHODS: 213 patients attending eight rheumatological centres in eight different European countries were studied. All had recently been referred and were considered by the senior investigator at each centre, selected because of their experience in treatment of PMR, to have this condition. By use of a standard international proforma, the requisite diagnostic points in each criteria set were sought. Sensitivity for each criterion from each set was then calculated, as well as the sensitivity of each criteria set as a whole. RESULTS: Of four criteria sets compared, the Bird (1979) criteria performed best with a sensitivity of 99.5%, and the Hunder (1982) criteria second best, with sensitivity of 93.3%. These both performed significantly better than the two other criteria sets, though each of these was admittedly developed for rather specialised reasons. CONCLUSIONS: Although this study compares homogeneity, we suggest the Bird 1979 or Hunder 1982 criteria should be used whenever possible. Studies that have used alternative criteria may have less sensitivity in diagnosis. 相似文献
147.
148.
The effects of granulocyte-macrophage colony-stimulating factor (GM- CSF) are not confined to cells of the myeloid lineage. GM-CSF has been shown to have effects on mature T cells and both mature and immature T- cell lines. We therefore examined the GM-CSF responsiveness of murine thymocytes to investigate whether GM-CSF also affected normal immature T lymphocytes. The studies presented here indicate that GM-CSF augments accessory cell (AC)-dependent T-cell receptor (TCR)-mediated proliferation of unseparated thymocyte populations. To identify the GM- CSF responsive cell type, thymic AC and T cells were examined for GM- CSF responsiveness. We found that GM-CSF augmentation of TCR-induced thymocyte proliferation appears to be mediated via augmentation of AC function, and not via direct effects on mature single-positive (SP) thymocytes. Enriched double-negative (DN) thymocytes were also tested for GM-CSF responsiveness. GM-CSF induced the proliferation of adult and fetal DN thymocytes in an AC-independent and TCR-independent single- cell assay. Thus, in contrast to the SP thymocytes, a DN thymocyte population was directly responsive to GM-CSF. GM-CSF therefore may play a direct role in the expansion of DN thymocytes and an indirect role in the expansion of SP thymocytes. 相似文献
149.
Verschraegen CF; Talpaz M; Hirsch-Ginsberg CF; Pherwani R; Rios MB; Stass SA; Kantarjian HM 《Blood》1995,85(10):2705-2710
The purpose of this report was to evaluate scintigraphy analysis of Southern blot hybridization as a method to quantify the breakpoint cluster region (BCR) rearrangement of Philadelphia chromosome (Ph)+ chronic myelogenous leukemia (CML). Cytogenetic and molecular studies performed simultaneously on 474 bone marrow and/or blood samples from 300 patients treated with alpha-interferon-based therapy were compared. Molecular results were expressed as the percentage of rearranged BCR bands versus the total scintigraphic signal. The percentage of Ph+ metaphases was calculated on 25 metaphases. The results of molecular studies obtained on both peripheral blood and bone marrow samples were identical. The rank correlation between the BCR quantification and the percentage of Ph positivity in 465 samples was excellent (r = .78). However, of 99 samples with a normal karyotype, 24% had a BCR rearrangement. Of 86 samples with no BCR rearrangement, 13% showed a Ph chromosome. Of 49 samples with partial cytogenetic remission (Ph+ metaphases, 1% to 34%), 23% had no BCR rearrangement. In samples with a minor or no cytogenetic response (Ph+ metaphases, > 34%), BCR analysis overestimated the degree of response in 73 of 326 samples (22%). Nevertheless, survival analysis by BCR quantification level showed statistically better outcome for patients in complete or partial molecular response (P < .01). Molecular quantification of BCR was useful in monitoring the course of Ph+ CML. This method, which can be used on peripheral blood, detected residual disease not shown by cytogenetic analysis and was prognostically relevant as a measure of disease suppression. 相似文献
150.
Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Foon KA; Schroff RW; Bunn PA; Mayer D; Abrams PG; Fer M; Ochs J; Bottino GC; Sherwin SA; Carlo DJ 《Blood》1984,64(5):1085-1093
A phase I clinical trial was initiated to treat patients with stage IV B-derived chronic lymphocytic leukemia (CLL) with the IgG2a murine monoclonal antibody T101. This antibody binds to a 65,000-mol wt (T65) antigen found on normal T lymphocytes, malignant T lymphocytes, and B- derived CLL cells. All of the patients had a histologically confirmed diagnosis of advanced B-derived CLL and were refractory to standard therapy, and more than 50% of their leukemia cells reacted with the T101 antibody in vitro. The patients received T101 antibody two times per week, over two to 50 hours by intravenous administration in 100 mL of normal saline containing 5% human albumin. Twelve patients were treated with a fixed dosage of 1, 10, 50, or 100 mg, and one patient was treated with 140 mg of antibody. It was demonstrated that patients given two-hour infusions of 50 mg developed pulmonary toxicity, with shortness of breath and chest tightness. This toxicity was eliminated when infusions of 50 or 100 mg of T101 were prolonged to 50 hours. All dose levels caused a rapid but transient decrease in circulating leukemia cell counts. In vivo binding to circulating and bone marrow leukemia cells was demonstrated at all dose levels with increased binding at higher dosages. Antimurine antibody responses were not demonstrated in any patients at any time during treatment. Circulating free murine antibody was demonstrated in the serum of only the two patients treated with 100 mg of antibody as a 50-hour infusion and the patient treated with 140 mg of antibody over 30 hours. Antigenic modulation was demonstrated in patients treated at all dose levels but was particularly apparent in patients treated with prolonged infusions of 50 and 100 mg of antibody. We were also able to demonstrate antigenic modulation in lymph node cells, which strongly suggests in vivo labeling of these cells. Overall, T101 antibody alone appears to have a very limited therapeutic value for patients with CLL. The observations of in vivo labeling of tumor cells, antigenic modulation, antibody pharmacokinetics, toxicity, and antimurine antibody formation may be used in the future for more effective therapy when drugs or toxins are conjugated to the antibody. 相似文献